The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | Pembrolizumab and epacadostat for NSCLC: ECHO-306/KEYNOTE-715
The European Lung Cancer Congress (ELCC) 2018, in Geneva, Switzerland, presented an array of exciting lung cancer trial updates. Speaking from the meeting, Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy, discusses the Phase III ECHO-306/KEYNOTE-715 study (NCT03322566). This promising trial comprises three arms and is investigating pembrolizumab and epacadostat in non-small cell lung cancer (NSCLC). Dr Garassino discusses the design, underlying rationale and primary endpoints of the study.
